J Gen Virol Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gill, D. K.
Right arrow Articles by Cason, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gill, D. K.
Right arrow Articles by Cason, J.
Agricola
Right arrow Articles by Gill, D. K.
Right arrow Articles by Cason, J.

Journal of General Virology, Vol 79, 1971-1976, Copyright © 1998 by Society for General Microbiology


ARTICLES

Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia

DK Gill, JM Bible, C Biswas, B Kell, JM Best, NA Punchard and J Cason
Department of Infection, Rayne Institute, Guy's Medical and Dental School, London, UK.

Proliferative responses to human papillomavirus type 16 (HPV-16) E5 peptides were determined for short-term cell lines derived from peripheral blood mononuclear cells of 75 women. Cell lines from 16 of the 75 women proliferated in response to stimulation with pooled E5 peptides; this was most common for patients with low-grade squamous cervical intraepithelial lesions (LSIL; 6 of 15 patients, 40%) and less frequent for asymptomatic women with no cervical lesions (4 of 20, 20%), those with high-grade squamous intraepithelial lesions(HSIL; 5 of 33, 15%) and others with cervical cancer (1 of 7, 14%, P = 0.027). Amongst these patients, proliferative responses were exclusive to those that were positive for HPV-16 DNA (12 of 41, 29%; c.f. none of 13 HPV- 16 DNA-negative subjects exhibited a proliferative response; P= 0023) and were again most prevalent amongst HPV-16 DNA-positive LSIL (6 of 14, 43%), as compared with HPV-16 DNA-positive HSIL (5 of 23, 22%) or HPV-16 DNA-positive cervical cancer patients (1 of 4, 25%, P > 0.05). In contrast, for asymptomatic women, responsiveness was statistically independent of HPV-16 DNA status, i.e. responsiveness in HPV-16 DNA- positive and DNA-negative subjects was observed in 3 of 15 (20%) and 1 of 5 (20%) cases, respectively (P > 0.05). There were no associations between detection of HPV-16 mRNA and proliferative responses (P> 0.05). These data suggest that HPV-16 E5-specific T-helper activity is depressed amongst women with HSIL lesions.


This article has been cited by other articles:


Home page
J. Virol.Home page
I. G. Bravo and A. Alonso
Mucosal Human Papillomaviruses Encode Four Different E5 Proteins Whose Chemistry and Phylogeny Correlate with Malignant or Benign Growth
J. Virol., December 15, 2004; 78(24): 13613 - 13626.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. Engelmark, A. Beskow, J. Magnusson, H. Erlich, and U. Gyllensten
Affected sib-pair analysis of the contribution of HLA class I and class II loci to development of cervical cancer
Hum. Mol. Genet., September 1, 2004; 13(17): 1951 - 1958.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
Y.-F. Chen, C.-W. Lin, Y.-P. Tsao, and S.-L. Chen
Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice
J. Virol., February 1, 2004; 78(3): 1333 - 1343.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
J. C. Luxton, R. Nath, N. Derias, A. Herbert, and P. S. Shepherd
Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment
J. Gen. Virol., May 1, 2003; 84(5): 1063 - 1070.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
M. Nakagawa, R. Viscidi, I. Deshmukh, M. D. Costa, J. M. Palefsky, S. Farhat, and A.-B. Moscicki
Time Course of Humoral and Cell-Mediated Immune Responses to Human Papillomavirus Type 16 in Infected Women
Clin. Vaccine Immunol., July 1, 2002; 9(4): 877 - 882.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
M. Scott, M. Nakagawa, and A.-B. Moscicki
Cell-Mediated Immune Response to Human Papillomavirus Infection
Clin. Vaccine Immunol., March 1, 2001; 8(2): 209 - 220.
[Full Text] [PDF]


Home page
J. Virol.Home page
D.-W. Liu, Y.-P. Tsao, C.-H. Hsieh, J.-T. Hsieh, J. T. Kung, C.-L. Chiang, S.-J. Huang, and S.-L. Chen
Induction of CD8 T Cells by Vaccination with Recombinant Adenovirus Expressing Human Papillomavirus Type 16 E5 Gene Reduces Tumor Growth
J. Virol., October 1, 2000; 74(19): 9083 - 9089.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 1998 by the Society for General Microbiology.